The estimated Net Worth of Thomas James Doyle is at least 1.02 百万$ dollars as of 29 January 2024. Mr Doyle owns over 2,318 units of Kura Oncology Inc stock worth over 956,089$ and over the last 3 years he sold KURA stock worth over 62,762$.
Mr has made over 2 trades of the Kura Oncology Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 2,318 units of KURA stock worth 41,260$ on 29 January 2024.
The largest trade he's ever made was selling 2,318 units of Kura Oncology Inc stock on 29 January 2024 worth over 41,260$. On average, Mr trades about 773 units every 73 days since 2022. As of 29 January 2024 he still owns at least 48,093 units of Kura Oncology Inc stock.
You can see the complete history of Mr Doyle stock trades at the bottom of the page.
Thomas Doyle is the Principal Accounting Officer & Sr. VP of Fin. and Accounting at Kura Oncology Inc.
Mr Doyle is 50, he's been the Principal Accounting Officer & Sr. VP of Fin. and Accounting of Kura Oncology Inc since . There are 14 older and 6 younger executives at Kura Oncology Inc. The oldest executive at Kura Oncology Inc is Kathleen Ford, 74, who is the Chief Operating Officer.
Thomas's mailing address filed with the SEC is C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA, 92130.
Over the last 6 years, insiders at Kura Oncology Inc have traded over 16,903,587$ worth of Kura Oncology Inc stock and bought 50,000 units worth 575,000$ . The most active insiders traders include Faheem Hasnain、Troy Edward Wilson、Mary T Szela. On average, Kura Oncology Inc executives and independent directors trade stock every 63 days with the average trade being worth of 626,260$. The most recent stock trade was executed by Teresa Brophy Bair on 20 May 2024, trading 2,615 units of KURA stock currently worth 57,922$.
at kura oncology, we are committed to realizing the promise of precision medicines for cancer. the genomics revolution is transforming how we treat cancer. we now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. this new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. we are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. our development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias. our goal is to help patients with cancer lead better, longer lives.
Kura Oncology Inc executives and other stock owners filed with the SEC include: